Yeeman K Ramtohul

This inventor holds 14 USPTO granted patents and 18 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Vertex Pharmaceuticals, Inc., Merck Frosst Canada, Inc., Aduro Biotech Inc.. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yeeman K Ramtohul. Retrieved from https://idiyas.com/inventor/yeeman-k-ramtohul

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 18)

% Patents Active = 64.3

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 6.9

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

9 out of 1,169

Vertex Pharmaceuticals, Inc.

patents

3 out of 212

Merck Frosst Canada, Inc.

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Cystic Fibrosis

Mannose Derivatives

Bacterial Infections

Inhibitors

Pyrazolopyrimidinone

Imidazopyridazines

Heteroaromatic Compounds

Azacycloalkane

Stearoyl-CoA

Delta-9 Desaturase

Drug Modulators

Chemical Compounds

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12324802 - Modulators of cystic fibrosis transmembrane conductance regulator (2025-06-10),

2. 12269831 - Modulators of cystic fibrosis transmembrane conductance regulator (2025-04-08),

3. 11634447 - Mannose derivatives for treating bacterial infections (2023-04-25),

4. 10913761 - 2,7-dibromospiro[fluorene-9,4'-piperidine] compounds (2021-02-09),

5. 10738056 - Pyrazolopyrimidinone compounds and uses thereof (2020-08-11),

6. 10669298 - Mannose derivatives for treating bacterial infections (2020-06-02),

7. 10030024 - Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway (2018-07-24),

8. 9963478 - Mannose derivatives for treating bacterial infections (2018-05-08),

9. 9890176 - Mannose derivatives for treating bacterial infections (2018-02-13),

10. 9598454 - Mannose derivatives for treating bacterial infections (2017-03-21),

11. 8063224 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2011-11-22),

12. 7799787 - Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2010-09-21),

13. 7754745 - Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2010-07-13),

14. 7582633 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2009-09-01),

Title: Yeeman K Ramtohul: Innovator in Cystic Fibrosis Research

Introduction

Yeeman K Ramtohul is a prominent inventor based in Pierrefonds, CA. He has made significant contributions to the field of medical research, particularly in the treatment of cystic fibrosis. With a total of 14 patents to his name, Ramtohul's work has had a profound impact on pharmaceutical development.

Latest Patents

One of his latest patents focuses on modulators of the cystic fibrosis transmembrane conductance regulator (CFTR). This disclosure provides modulators of CFTR, pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using these modulators and pharmaceutical compositions, and processes for making such modulators. This innovative approach aims to improve the quality of life for individuals suffering from cystic fibrosis.

Career Highlights

Throughout his career, Yeeman K Ramtohul has worked with leading pharmaceutical companies, including Vertex Pharmaceuticals, Inc. and Merck Frosst Canada, Inc. His experience in these organizations has allowed him to develop groundbreaking treatments and contribute to advancements in medical science.

Collaborations

Some of his notable coworkers include Thumkunta Jagadeeswar Reddy and Michel Gallant. Their collaborative efforts have further enhanced the research and development of effective treatments for cystic fibrosis.

Conclusion

Yeeman K Ramtohul's innovative work in the field of cystic fibrosis research exemplifies the importance of dedicated inventors in advancing medical science. His contributions continue to pave the way for new treatments and improved patient outcomes.

Profile summary based on public USPTO records.